Characterization of topoisomerase IIα gene amplification and deletion in breast cancer

Genes Chromosomes and Cancer

Volumn 26, Issue 2, 1999, Pages 142-150

  Järvinen, Tero A H ^a,c   Tanner, Minna ^a,b   Bärlund, Maarit ^a   Borg, Åke ^b   Isola, Jorma ^a,b  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY OF TAMPERE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING);

ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; DNA REPLICATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DELETION; HUMAN; HUMAN CELL; ONCOGENE NEU; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ANTIGENS, NEOPLASM; BLOTTING, SOUTHERN; BREAST NEOPLASMS; CHROMOSOME MAPPING; DNA TOPOISOMERASES, TYPE II; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; GENE AMPLIFICATION; GENE DELETION; GENE DOSAGE; GENES, ERBB-2; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; ISOENZYMES; METAPHASE; TUMOR CELLS, CULTURED;

EID: 0043145754     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1098-2264(199910)26:2<142::aid-gcc6>3.3.co;2-2     Document Type: Article

References (49)

1. Asano T, An T, Mayes J, Zwelling LA, Kleinerman ES. 1996a. Transfection of human topoisomerase IIa into etoposide-resistant cells: transient increase in sensitivity followed by down-regulation of the endogenous gene. Biochem J 319:307-313.
2. Asano T, Zwelling LA, An T, McWatters A, Herzog CE, Mayes J, Loughlin SM, Kleinerman ES. 1996b. Effect of transfection of a drosophila topoisomerase II gene into a human brain tumour cell line intrinsically resistant to etoposide. Br J Cancer 73:1373-1380.
3. Baldetorp B, Fernö M, Fallenius A, Fallenius-Vecchi G, Idvall I, Olsson H, Sigurdsson H, Åkerman M, Killander D. 1992. Image cytometric DNA analysis in human breast cancer analysis may add prognostic information in diploid cases with low S-phase fraction by flow cytometry. Cytometry 13:577-585.
4. Bärlund M, Tirkkonen M, Forozan F, Tanner MM, Kallioniemi O, Kallioniemi A. 1997. Increased copy number at 17q22-q24 by CGH in breast cancer is due to high-level amplification of two separate regions. Genes Chromosomes Cancer 20:372-376.
5. Bärlund M, Nupponen NN, Karhu R, Tanner MM, Paavola P, Kallioniemi O, Kallioniemi A. 1998. Molecular cytogenetic mapping of 24 CEPH YACs and 24 gene-specific large insert probes to chromosome 17. Cytogenet Cell Genet 82:189-191.
6. Bautista S, Theillet C. 1998. CCND1 and FGFR1 coamplification results in the colocalization of 11q13 and 8p12 sequences in breast tumor nuclei. Genes Chromosomes Cancer 22:268-277.
7. Bièche I, Tomasetto C, Régnier CH, Moog-Lutz C, Rio M-C, Lidereau R. 1996. Two distinct amplified regions at 17q11-q21 involved in human primary breast cancer. Cancer Res 56:3886-3890.
8. Borg Å, Baldetorp B, Fernö M, Killander D, Olsson H, Sigurdsson H. 1991. ERBB2 amplification in breast cancer with a high rate of proliferation. Oncogene 6:137-143.
9. Clahsen PC, van de Velde JH, Duval C, Pallud C, Mandard A-M, Delobelle-Deroide A, van den Broek L, Sahmoud TM, van de Vijver MJ. 1998. p53 protein accumulation and response to adjuvant chemothetapy in premenopausal women with node-negative early breast cancer. J Clin Oncol 16:470-479.
10. Coquelle A, Pipiras E, Toledo F, Buttin G, Debatisse M. 1997. Expression of fragile sites triggers intrachromosomal mammalian gene amplification and sets boundaries to early amplicons. Cell 89:215-225.
11. Courjal F, Cuny M, Simony-Lafontaine J, Louason G, Speiser P, Zeillinger R, Rodriquez C, Theillet C. 1997. Comparative genomic hybridization analysis of breast tumors with predetermined profiles of DNA amplification. Cancer Res 57:4153-4445.
12. Davies SM, Robson CN, Davies SL, Hickson ID. 1988. Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins. J Biol Chem 263:17724-17729.
13. Falkson G, Gelman R, Falkson CI, Glick J, Harris J. 1991. Factors predicting for response, time to treatment failure and survival in women with metastatic breast cancer treated with DAVTH: a prospective eastern cooperative oncology group study. J Clin Oncol 9:2153-2161.
14. Froelich-Ammon SJ, Osheroff N. 1995. Topoisomerase poisons: harnessing the dark side of enzyme mechanism. J Biol Chem 270:21429-21432.
15. Gudkov AV, Zelnick CR, Kazarov AR, Thimmapaya R, Suttle DP, Beck WT, Robinson IB. 1993. Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA. Proc Natl Acad Sci USA 90:3231-3235.
16. Heiskanen M, Hellsten E, Kallioniemi O-P, Mäkelä TP, Alitalo K, Peltonen L, Palotie A. 1995. Visual mapping by fiber-FISH. Genomics 30:31-36.
17. Hoare SF, Freeman CA, Coutts JC, Varley JM, James L, Keith WN. 1997. Identification of genetic changes associated with drug resistance by reverse in situ hybridization. Br J Cancer 75:275-282.
18. Hohaus S, Funk L, Martin S, Schienk RF, Abdullah A, Hahn U, Egerer G, Goldschmidt H, Schneeweiss A, Fersis N, Wallwiener D, Bastert G, Haas R. 1999. Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer. Br J Cancer 79:1500-1507.
19. Horelli-Kuitunen N, Aaltonen J, Yaspo ML, Eeva M, Wessman M, Peltonen L, Palotie A. 1999. Mapping ESTs by fiber-FISH. Genome Res 9:62-71.
20. Järvinen TAH, Kononen J, Pelto-Huikko M, Isola J. 1996. Expression of topoisomerase IIα is associated with rapid cell proliferation, aneuploidy, and c-erbB-2 overexpression in breast cancer. Am J Pathol 148:2073-2082.
21. Järvinen TAH, Holli K, Kuukasjärvi T, Isola JJ. 1998. Predictive value of topoisomerase IIα and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br J Cancer 72:2267-2273.
22. Järvinen TAH, Tanner M, Rantanen V, Bärlund M, Borg Å, Grénman S, Isola J. 1999. Amplification and deletion of topoisomeraseIIα associate with ErbB-2 amplification and correlate with sensitivity to doxorubicin in breast cancer. Submitted.
23. Jin Y, Höglund M, Jin C, Martins C, Wennerberg J, Åkervall J, Mandahl N, Mitelman F, Mertens F. 1998. FISH characterization of head and neck carcinomas reveals that amplification of band 11q13 is associated with deletion of distal 11q. Genes Chromosomes Cancer 22:312-320.
24. Keith WN, Douglas F, Wishart GC, McCallum HM, George WD, Kaye SB, Brown R. 1993. Co-amplification of ERBB2, topoisomerase II and retinoid acid receptor genes in breast cancer and allelic loss at topoisomerase I on chromosome 20. Eur J Cancer 29A:1469-1475.
25. Liang F, Han M, Romanienko PJ, Jasin M. 1998. Homology-directed repair is a major double-strand break repair pathway in mammalian cells. Proc Natl Acad Sci USA 95:5172-5177.
26. MacGrogan G, Mauriac L, Durand M, Bonichon F, Trojani M, de Mascarel I, Coindre JM. 1996. Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GSTπ. Br J Cancer 74:1458-1465.
27. Mo YY, Ameiss KA, Beck WT. 1998. Overexpression of human DNA topoisomerase IIα by fusion to enhanced green fluorescent protein. Biotechniques 25:1052-1057.
28. Morton NE. 1991. Parameters of the human genome. Proc Natl Acad Sci USA 88:7474-7476.
29. Murphy DS, McHardy P, Coutts J, Mallon EA, George WD, Kaye SB, Brown R, Keith WN. 1996. Interphase cytogenetic analysis of ERBB2 and TOP2A co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ. Int J Cancer 64:18-26.
30. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, Henderson IC. 1994. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260-1266.
31. Pauletti G, Godolphin W, Press MF, Slamon DJ. 1996. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 13:63-72.
32. Pinkel D, Segraves R, Sudar D, Clark S, Poole I, Kowbel D, Collins C, Kuo WL, Chen C, Zhai Y, Dairkee SH, Ljung BM, Gray JW, Albertson DG. 1998. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet 20:207-211.
33. Pipiras E. Coquelle A, Bieth A, Debatisse M. 1998. Interstitial deletions and intrachromosomal amplification initiated from a double-strand break targeted to a mammalian chromosome. EMBO J 17:325-333.
34. Plummer SJ, Paris MJ, Myles J, Tubbs R, Crowe J Casey G. 1997. Four regions of allelic imbalance on 17q12-qter associated with high-grade breast tumors. Genes Chromosomes Cancer 20:354-362.
35. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou J-Y, Ma Y, Hung G, Robinson RA, Harris C, El-Naggar A, Slamon DJ, Phillips RN, Ross JS, Wolman SR, Flom KJ. 1997. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 15:2894-2904.
36. Raap AK. 1998. Advances in fluorescence in situ hybridization. Mutat Res 25:287-298.
37. Smith K, Houlbrook S, Greenall M, Carmichael J, Harris AL. 1993. Topoisomerase IIa co-amplification with ERBB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity. Oncogene 8:933-938.
38. Stokke T, Collins C, Kuo W-L, Kowbel D, Shadravan F, Tanner M, Kallioniemi A, Pinkel D, Deaven L, Gray JW. 1995. A physical map of chromosome 20 established using fluorescence in situ hybridization and digital image analysis. Genomics 26:134-137.
39. Tanner MM, Tirkkonen M, Kallioniemi A, Collins C, Stokke T, Karhu R, Kowbel D, Shadravan F, Hintz M, Kuo W-L, Waldman F, Isola JJ, Gray JW, Kallioniemi O-P. 1994. Increased copy number at 20q13 in breast cancer: defining the critical region and exclusion of candidate genes. Cancer Res 54:4257-4260.
40. Tanner MM, Tirkkonen M, Kallioniemi A, Isola J, Kuukasjärvi T, Collins C, Kowbel D, Guan X-Y, Trent J, Gray JW, Meltzer P, Kallioniemi O-P. 1996. Independent amplification and frequent co-amplification of three nonsyntenic regions on the long arm of chromosome 20 in breast cancer. Cancer Res 56:3441-3445.
41. Tanner MM, Karhu RA, Nupponen NN, Borg Å, Baldetorp B, Pejovic T, Fernö M, Killander D, Isola JJ. 1998. Genetic aberrations in hypodiploid breast cancer: frequent loss of chromosome 4 and amplification of cyclin D1 oncogene. Am J Pathol 153:191-199.
42. Tomasetto C, Regnier C, Moog-Lutz C, Mattei MG, Chenard MP, Liderau S, Basset P, Rio MC. 1995. Identification of four novel human genes amplified and overexpressed in breast carcinoma and located to the q11-q21.3 region of chromosome 17. Genomics 28:367-376.
43. van de Vijver MJ, van de Bersselaar R, Devilee P, Cornelisse C, Peterse J, Nusse R. 1987. Amplification of the neu (c-ERBB2) oncogene in human mammary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. Mol Cell Biol 7:2019-2023.
44. Vassetzky YS, Alghisi G-C, Roberts E, Gasser SM. 1996. Ectopic expression of inactive forms of yeast DNA topoisomerase II confers resistance to the anti-tumour drug-etoposide. Br J Cancer 73:1201-1209.
45. Vidgren V, Varis A, Kokkola A, Monni O, Puolakkainen P, Nordling S, Forozan F, Kallioniemi A, Vakkari M-L, Kivilaakso E, Knuutila S. 1999. Concominant gastrin and ERBB2 gene amplifications at 17q12-q21 in the intestinal type of gastric cancer. Genes Chromosomes Cancer 24:24-29.
46. Wang JC. 1996. DNA topoisomerases. Ann Rev Biochem 65:635-692.
47. Withoff S, Keith WN, Knol AJ, Coutts JC, Hoare SF, Mulder NH, de Vries EGE. 1996a. Selection of a subpopulation with fewer DNA topoisomerase IIα gene copies in a doxorubicin-resistant cell line panel. Br J Cancer 74:502-507.
48. Withoff S, de Vries EGE, Keith WN, Nienhuis EF, van der Graaf WTA, Uges DRA, Mulder NH. 1996b. Differential expression of DNA topoisomerase IIα and -ß in P-gn and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC. Br J Cancer 74:1869-1876.
49. Yang X, Uziely B, Groshen S, Lukas J, Israel V, Russell C, Dunnington G, Formenti S, Muggia F, Press MF. 1999. MDR1 gene expression in primary and advanced breast cancer. Lab Invest 79:271-280.